Scandinavian ChemoTech

The approved patent protects both the unique probe, which the doctor and veterinarian hold, as well as the unique electrodes (needles) that are used to deliver the dynamic and tumour specific pulse in the treatment of patients.

The probe has unique properties that allow the user to adjust how large of an area that is subject for treatment. Since the electrodes can be attached in various configurations in the same probe, Scandinavian ChemoTech can create significant cost benefits for healthcare providers. This is because the clinics do not have to buy several different accessories to be able to carry out the TSE treatments. This applies to both the company's Human Care and Animal Care operations.

The innovators behind this patent are Mohan Frick, Bertil Persson and Johan Marnfeldt.

"The fact that the Company continues to develop and achieve new successes in the patent portfolio feels really good for our future market establishments. As we are currently establishing our TSE technology for animal care in the US, this patent could be of great importance for ChemoTech in the future." - says Mohan Frick, CEO of Scandinavian ChemoTech.

For further information please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

E-mail: ir@chemotech.se

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.